Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

Meriofert is a gonadotropin used in reproductive medicine to address disorders of follicular development and ovulation.

• Infertility due to anovulation: promotes follicular growth and induces ovulation.
• Assisted reproductive technology (ART): supports controlled ovarian stimulation for IVF cycles.
• Hypogonadotropic hypogonadism: replaces deficient endogenous FSH and LH to restore normal gonadal function.

• Meriofert contains recombinant Follicle‑Stimulating Hormone and Luteinising Hormone that bind to their respective receptors on ovarian granulosa and theca cells. Activation of FSH receptors stimulates follicular maturation, while LH receptor activation triggers ovulation and luteal phase support, thereby facilitating normal reproductive cycling.

Adverse reactions may occur with any injectable gonadotropin therapy.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Headache: transient, often resolves without intervention.
• Nausea: occasional, usually mild.
• Abdominal bloating: temporary abdominal distension.
• Mood changes: mild emotional fluctuations.

Serious or Rare Side Effects

• Ovarian hyperstimulation syndrome (OHSS): potentially severe fluid shift and organ involvement.
• Thromboembolic events: rare clot formation in veins.
• Allergic reaction: rash, urticaria, or anaphylaxis.
• Ectopic pregnancy: rare occurrence during assisted reproduction.
• Multiple pregnancy: increased risk of twins or higher-order gestations.

Meriofert should be used under specialist supervision with attention to patient‑specific risk factors.

• Pregnancy testing: confirm non‑pregnant status before initiating therapy.
• OHSS monitoring: assess for signs of ovarian hyperstimulation during treatment.
• Thrombotic risk: evaluate personal or family history of clotting disorders.
• Allergic history: screen for hypersensitivity to any component of the formulation.
• Storage: Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions may modify the efficacy or safety of Meriofert.

Major Interactions (Avoid)

• GnRH antagonists: may blunt the intended gonadotropin response.
• High‑dose estrogen therapy: can suppress endogenous gonadotropin activity.

Moderate Interactions (Monitor Closely)

• Anticoagulants: monitor for increased bleeding risk if OHSS occurs.
• Corticosteroids: may affect fluid balance during ovarian stimulation.
• Thyroid hormones: adjust dosing if thyroid dysfunction is present.